Mayne Pharma Group (ASX:MYX) said that it has been served with a legal proceeding filed in the US District Court of Delaware against its US unit, Mayne Pharma, according to a Friday filing with the Australian bourse.
The lawsuit filed by US-based women's healthcare company TherapeuticsMD (TXMD) alleges breach of contract, fraudulent inducement, and unjust enrichment related to the 2022 transaction agreement between the companies, the filing said.
The company plans to vigorously defend the case, which it believes is without merit, the filing added.
MYX also stated it had separate claims against TXMD, alleging damages exceeding TXMD's claims.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.